Novo Nordisk price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan
JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...
JPMorgan cuts Novo Nordisk target, keeps Overweight rating
JPMorgan analysts revised their outlook on Novo Nordisk (NYSE:NVO) stock, reducing the price target to DKK1,000 from DKK1,050. Despite the adjustment, they maintained an Overweight rating on the ...
Hims & Hers Health down as Super Bowl ad draws controversy
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Market movers: Stocks seeing action on Thursday - and why
The U.S. drugmaker’s shares were up in Thursday trading. The stock has more than doubled in value in the last two years, ...
Allstate Reports Fourth Quarter and Full Year 2024 Results
The Allstate Corporation (NYSE: ALL) today reported financial results for the fourth quarter of 2024. The Allstate Corporation Consolidated Highlights ...